GeneLancet Biosciences
As a company specializing in CRISPR gene editing, GeneLancet Biosciences owns a novel single molecule guide RNA (LgRNA) of distinct intellectual property and develops STAR Editors (novel RGENs) for biological and therapeutic applications.
Our Management Team is composed of experts with gene editing research and industry experiences.
Ms. Sheri Lin Founder/COO
- 24 years of operational experience in fortune 500 and early stage companies
Dr.Minghong Zhong Founder/CEO
- Inventor of LgRNA technology
- 25 years of drug discovery in biopharmaceutical companies
- Adjunct professor of translational medicine, Baruch S. Blumberg Institute
Dr.Randall HyerCTO
- SVP at Moderna (mRNA COVID-19 vaccine)
- FDA (and later EMA) approvals of the two-dose hep B vaccine
- 20+year in biotechnology development
Dr. Scott StrobelScientific Advisor
- Professor of Biochemistry & Biophysics, Chemistry, Yale University
- Yale University Provost
- Leading expertise in RNA chemistry and biology
Dr. Leonid BeigelmanScientific Advisor
- Top executive in major biopharmaceutical companies
- Leading expertise in Discovery and Development of Nucleic Acid Therapeutics and Small Molecules Antivirals
